Banner

Article

Linagliptin cardiovascular safety profile appears superior to glimepiride

Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.

Related Videos
Related Content
Reproduced with permission from Novocure GmbH ©2022 Novocure GmbH – All rights reserved.
October 17th 2024

FDA approves treatment for lung cancer that disrupts cancer cells with electric fields

Ep 41: Burnout with Roger Kapoor, MD
October 7th 2024

Ep 41: Burnout with Roger Kapoor, MD

Estate planning tips: ©Vitalii Vodolazsky - stock.adobe.com
October 17th 2024

Estate planning is your first line of defense against wealth loss—Here’s what you should know

Ep 40: Malpractice caps and nuclear verdicts with Bob White, the Doctors Company
September 20th 2024

Ep 40: Malpractice caps and nuclear verdicts with Bob White, the Doctors Company

UNCOVER 35% MORE INCOME
October 17th 2024

UNCOVER 35% MORE INCOME

muddy racers: © pavel1964 - stock.adobe.com
October 17th 2024

Breast cancer treatment and aging; ‘concepts of a plan;’ extreme exercise and health – Morning Medical Update